Tyrosine Kinase Inhibitors: all 10,744 studies that test it

Page 94 of 108. Open to participants first (1,949), then studies with results posted, then the rest; newest registration first within each.

• Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy VolunteersCompletedNCT01204112Phase 1
• A Study of Nilotinib in Growing Vestibular SchwannomasTerminatedNCT01201538Phase 2
• Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome ResistanceCompletedNCT01197170Phase 1
• Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung CancerCompletedNCT01196234Phase 2
• RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerTerminatedNCT01193881Phase 1
• A Study of Apatinib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT01192971Phase 2
• Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer PatientsStatus unknownNCT01192243Phase 2
• Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-PaclitaxelCompletedNCT01192165Phase 1
• Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract CancerCompletedNCT01191892Phase 2
• A Study to Evaluate the Drug Interaction of ASP015K and TacrolimusCompletedNCT01190670Phase 1
• Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer PatientsStatus unknownNCT01189903Phase 2/3
• RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.WithdrawnNCT01188889Phase 1/2
• A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung CancerTerminatedNCT01188707Phase 1/2
• Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung CancerTerminatedNCT01187615Phase 1
• Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATECompletedNCT01187212Phase 2
• Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced CancerActive, not recruitingNCT01187199Phase 1
• Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based ChemotherapyCompletedNCT01186861Phase 2
• Pharmacokinetics And Safety Study Of Two CP-690,550 Controlled Release Formulation Following Single Dose In Healthy VolunteersCompletedNCT01185184Phase 1
• A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell CarcinomaCompletedNCT01185158Phase 2
• Lapatinib and Cetuximab in Patients With Solid TumorsCompletedNCT01184482Phase 1
• Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)CompletedNCT01183663Phase 1
• Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by SurgeryStatus unknownNCT01182272Phase 2
• AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic CancerStatus unknownNCT01182246Phase 1/2
• A Study to Assess Drug Interaction of ASP015K and MidazolamCompletedNCT01182077Phase 1
• First-in-Human Single Ascending and Multiple Dose of GLPG0634CompletedNCT01179581Phase 1
• Pazopanib and Paclitaxel for Non-Small Cell Lung CancerWithdrawnNCT01179269Phase 2
• Effect of Supplemental Oral Curcumin in Patients With Atopic AsthmaCompletedNCT01179256Not applicable
• Study of Apatinib in Metastatic Triple-Negative Breast Cancer PatientsCompletedNCT01176669Phase 2
• Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent ChordomaStatus unknownNCT01175109Phase 1
• Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)CompletedNCT01172548Phase 2
• Primary Chemotherapy in Patients With HER2-positive Early Breast CancerCompletedNCT01172223Phase 1/2
• Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT01170104Phase 2
• Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) DiseaseCompletedNCT01168440Phase 2
• Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.Status unknownNCT01168050Phase 2
• Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior ResponseCompletedNCT01167244Phase 2
• Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid TumorsCompletedNCT01165385Phase 1
• Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian CancerCompletedNCT01164995Phase 2
• INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative DiseaseCompletedNCT01164163Phase 1
• A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer PatientsTerminatedNCT01161368Phase 2
• Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY TrialTerminatedNCT01160926Phase 1
• Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction ChemotherapyTerminatedNCT01159327Phase 2
• Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT01159301Phase 1
• Sorafenib. ICORG 06-41, V4CompletedNCT01158287Phase 2
• Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host DiseaseCompletedNCT01155817Phase 1
• Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid TumorsCompletedNCT01155713Phase 1
• A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular DegenerationCompletedNCT01154062Phase 1
• Efficacy of Imatinib and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile DuctCompletedNCT01153750Phase 2
• A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg TabletsCompletedNCT01153659Phase 1
• PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric CancerCompletedNCT01152853Phase 2
• Study of ARQ 197 MonotherapyCompletedNCT01152645Phase 2
• Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid TumorsCompletedNCT01149720Phase 1
• Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib (Tarceva) in Advanced Biliary Tract CarcinomaCompletedNCT01149122Phase 3
• A Study of Foretinib in Patients With Recurrent/Metastatic Breast CancerCompletedNCT01147484Phase 2
• Japanese Phase 1 Study of BMS-844203 (CT322)WithdrawnNCT01146171Phase 1
• Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal CancerTerminatedNCT01145404Phase 2
• Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)CompletedNCT01144260Phase 2
• A Study To Estimate The Amount Of CP-690,550 (Study Drug) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet FormCompletedNCT01143805Phase 1
• Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid CancerActive, not recruitingNCT01141309Phase 2
• A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue SarcomasCompletedNCT01140737Phase 2
• Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast CancerCompletedNCT01138384Phase 1/2
• Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid TumorsCompletedNCT01138033Phase 1
• A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast CancerWithdrawnNCT01137994Phase 2
• Study to Evaluate Imatinib in Desmoid TumorsCompletedNCT01137916Phase 2
• Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT01135056Phase 3
• A Study in Myeloproliferative DisordersCompletedNCT01134120Phase 1
• Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®) (PGT)CompletedNCT01133912Phase 1
• Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular CarcinomaCompletedNCT01131689Phase 1
• A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR MutationsStatus unknownNCT01131429Phase 2
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• The Continuation of ErlotinibStatus unknownNCT01130779Phase 2
• Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung CancerCompletedNCT01130753Phase 2
• A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid TumorsWithdrawnNCT01130623Phase 1
• Sorafenib Plus S-1 in Advanced Solid TumorsCompletedNCT01128998Phase 1
• A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseCompletedNCT01126892Phase 3
• A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid LeukemiaCompletedNCT01126814Phase 1/2
• A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult VolunteersCompletedNCT01125904Phase 1
• Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction CancerTerminatedNCT01123473Phase 2
• Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)CompletedNCT01122615Phase 1
• Treatment of Polycythemia Vera With GleevecCompletedNCT01120821Phase 2
• Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract CancerStatus unknownNCT01118039Phase 2
• Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative TreatmentCompletedNCT01116843Phase 1/2
• Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive TractCompletedNCT01116622Phase 1
• Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & NeckCompletedNCT01116336Phase 1
• Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).CompletedNCT01116219Phase 2
• Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma PatientsTerminatedNCT01116128Phase 2
• A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)CompletedNCT01114191Phase 1
• PF-00299804 in Adult Patients With Relapsed/Recurrent GlioblastomaCompletedNCT01112527Phase 2
• Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid TumoursTerminatedNCT01112397Phase 1
• Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)CompletedNCT01110668Phase 2
• First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid TumorsTerminatedNCT01110083Phase 1
• Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib TreatmentTerminatedNCT01108705Phase 3
• Study of Oral ENMD-2076 Administered to Patients With Ovarian CancerCompletedNCT01104675Phase 2
• Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast CancerActive, not recruitingNCT01104571Phase 3
• Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant GliomaTerminatedNCT01103375Phase 1
• CP-690,550 Pharmacokinetics In Healthy Chinese SubjectsCompletedNCT01101919Phase 1
• A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCCTerminatedNCT01101906Phase 2
• A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid TumorsCompletedNCT01100619Phase 1
• Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma PatientsCompletedNCT01100177Phase 2
• Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine TumorCompletedNCT01099540Phase 2
• Study of Nilotinib in Metastatic Melanoma With KIT AberrationsCompletedNCT01099514Phase 2

← Tyrosine Kinase Inhibitors overview